Resistance to the tubulin-binding agents in renal cell carcinoma: No mutations in the class I β-tubulin gene but changes in tubulin isotype protein expression

Clinical Cancer Research

Volumn 11, Issue 9, 2005, Pages 3439-3445

  Ferguson, Roisean E ^a   Taylor, Claire ^a   Stanley, Anthea ^a   Butler, Elizabeth ^a   Joyce, Adrian ^b   Harnden, Patricia ^a   Patel, Poulam M ^a   Selby, Peter J ^a   Banks, Rosamonde E ^a,b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; DNA; PACLITAXEL; VINBLASTINE;

ADULT; AGED; ARTICLE; BETA TUBULIN GENE; CANCER CELL CULTURE; CANCER RESISTANCE; CORRELATION ANALYSIS; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; KIDNEY CARCINOMA; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOGENE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN ISOFORMS; TUBULIN;

EID: 18244364381     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2049     Document Type: Article

References (41)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. J Clin 2001;51:15-36.
2. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998;352:1691-6.
3. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166: 1611-23.
4. Cancer Research UK. Cancer Stats 2005. www. cancerresearchuk.org/ aboutcancer/statistics/incidence.
5. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-17.
6. Luduena RF. Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 1998;178:207-75.
7. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anti-Canc Agents 2002;2:1-17.
8. Ferguson RE, Jackson SM, Stanley AJ, et al. Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. Int J Cancer 2005;115:155-63.
9. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of taxol resistance related to microtubules. Oncogene 2003;22:7280-95.
10. Burkhart CA, Kavallaris M, Band HS. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001;1471:1-9.
11. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999;80:1020-5.
12. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997;100:1282-93.
13. Berrieman HK, Lind MJ, Cawkwell L. Do β-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 2004;5:158-64.
14. Drukman S, Kavallaris M. Microtubule alterations and resistance to tubulin-binding agents (Review). Int J Oncol 2002;21:621-8.
15. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-25.
16. He L, Orr GA, Horwitz SB. Novel molecules that interact with microtubules and have functional activity similar to Taxol. Drug Discov Today 2001;6: 1153-64.
17. Kavallaris M, Tait AS, Walsh BJ, et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 2001; 61:5803-9.
18. Hua XH, Genini D, Gussio R, et al. Biochemical genetic analysis of indanocine resistance in human leukemia. Cancer Res 2001;61:7248-54.
19. Kelley MJ, Li S, Harpole DH. Genetic analysis of the β-tubulin gene, TUBB, in non-small-cell lung cancer. J Natl Cancer Inst 2001;93:1886-8.
20. Tsurutani J, Komiya T, Uejima H, et al. Mutational analysis of the β-tubulin gene in lung cancer. Lung Cancer 2002;35:11-6.
21. Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with β-tubulin gene mutations. J Clin Oncol 1999;17: 1786-93.
22. Hasegawa S, Miyoshi Y, Egawa C, et al. Mutational analysis of the class I β-tubulin gene in human breast cancer. Int J Cancer 2002;101:46-51.
23. Sale S, Sung R, Shen P, et al. Conservation of the class I β-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther 2002;1:215-25.
24. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified β-tubulin isotypes. Biochem 1997; 36:3554-62.
25. Hasegawa S, Miyoshi Y, Egawa C, et al. Prediction of response to docetaxel by quantitative analysis of class I and III β-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003;9:2992-7.
26. TNM classification of malignant tumors. 6th ed. In: Sobin LH, Wittekind Ch, editors. Italy: Unio Internationale Contra Cancrum; 2002.
27. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
28. Ferguson RE, Carroll HP, Harris A, Maher ER, Selby PJ, Banks RE. Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics 2005;5: 566-71.
29. Banks RE, Craven RA, Harnden PA, Selby PJ. Use of a sensitive EnVision™+-based detection system for Western blotting: avoidance of streptavidin binding to endogenous biotin and biotin-containing proteins in kidney and other tissues. Proteomics 2003;3:558-61.
30. Nogales E. Structural insight into microtubule function. Annu Rev Biophys Biomol Struct 2001;30: 397-420.
31. Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 2000;19:3078-85.
32. Verrills NM, Flemming CL, Liu M, et al. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol 2003;10:597-607.
33. Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 2000;97:2904-9.
34. Maeno K, Ito K, Hama Y, et al. Mutation of the class I β-tubulin gene does not predict response to paclitaxel for breast cancer. Cancer Lett 2003;198:89-97.
35. Urano N, Fujiwara Y, Hasegawa S, et al. Absence of β-tubulin gene mutation in gastric carcinoma. Gastric Cancer 2003;6:108-12.
36. Kohonen-Corish MR, Qin H, Daniel JJ, et al. Lack of β-tubulin gene mutations in early stage lung cancer. Int J Cancer 2002;101;398-9.
37. Belda-Iniesta C, Perona R, de Castro CJ, et al. Do β-tubulin pseudogenes really matter? Lancet Oncol 2004;5:271-2.
38. Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR. Increase of β(III)- and β(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 1996;56:2584-9.
39. Ranganathan S, McCauley RA, Dexter DW, Hudes GR. Modulation of endogenous β-tubulin isotype expression as a result of human β(III)cDNA transfection into prostate carcinoma cells. Br J Cancer 2001;85: 735-40.
40. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997;18:533-7.
41. Blade K, Menick DR, Cabral F. Overexpression of Class I, II or IVb β-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel. J Cell Sci 1999;112:2213-21.